Shortage of Clindamycin Phosphate Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Clindamycin Phosphate Injection, an anti-infective medication, with some presentations limited or unavailable from manufacturers.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Clindamycin Phosphate Injection) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
The drug in shortage is Clindamycin Phosphate Injection, with brand names CLEOCIN PHOSPHATE and CLINDAMYCIN PHOSPHATE. It is available in injection dosage form and falls under the therapeutic category of Anti-Infective. The shortage status is current, with the initial posting date of 03/21/2023 and last updated on 03/27/2026.
Which Manufacturers Are Affected
Pfizer Inc. has multiple presentations affected:
- Limited Availability for Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06), with next delivery in September 2026 and estimated recovery in September 2026. Contact: 800-533-4535.
- Available for Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26). Contact: 800-533-4535.
- Unavailable for Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26), with next delivery in April 2026 and estimated recovery in June 2026. Contact: 800-533-4535.
- Unavailable for Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04), with next delivery in July 2026 and estimated recovery in September 2026. Contact: 800-533-4535.
- Unavailable for Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02), with next delivery in July 2026 and estimated recovery in September 2026. Contact: 800-533-4535.
- Available for Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18). Contact: 800-533-4535.
Baxter Healthcare has:
- Available for Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50). Contact: 888-229-0001.
- Available for Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50). Contact: 888-229-0001.
- Unavailable for Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50), with estimated recovery in May 2026. Contact: 888-229-0001.
- Unavailable for Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50), with estimated recovery in April 2026. Contact: 888-229-0001.
Why There's a Shortage
The reason for the shortage is listed as 'Other.' No specific details were provided in the source.
What Patients Should Do
If you rely on Clindamycin Phosphate Injection, we recommend speaking with your pharmacist to check availability and discuss options. You may also contact the manufacturer directly using the provided numbers to inquire about supply. Remember, patients should consult their healthcare provider for any guidance on their treatment; this article does not provide medical advice.
Source
This information is sourced from the FDA Drug Shortage Database, with the shortage initially posted on 03/21/2023 and last updated on 03/27/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.